Mutational activation of the RAS (RAS viral oncogene homolog)/RAF (Rapidly Accelerated Fibrosarcoma kinase/MAPK (Mitogen activated protein kinase) pathways occurs in the majority of melanomas with acquired resistance. This evidence concerns the gene WNK2 and melanoma.